Bullous disorders associated with PD-1 and PD-L1 inhibitors: Pharmacovigilance analysis of the United States Food and Drug Administration Adverse Event Reporting System from the Research on Adverse Drug Events And Reports Program Research Letter
| Authors: | Jimenez, J.; Gwillim, E. C.; Kosche, C.; Figueiredo, A.; Rauck, C.; Rangel, S. M.; Choi, J.; West, D. P.; Nardone, B.; Lacouture, M. E. |
| Title: | Bullous disorders associated with PD-1 and PD-L1 inhibitors: Pharmacovigilance analysis of the United States Food and Drug Administration Adverse Event Reporting System from the Research on Adverse Drug Events And Reports Program |
| Keywords: | food and drug administration; bullous skin disease; nivolumab; human; priority journal; article; pembrolizumab; durvalumab; atezolizumab; avelumab; antineoplastic monoclonal antibody; pharmacovigilance |
| Journal Title: | Journal of the American Academy of Dermatology |
| Volume: | 83 |
| Issue: | 3 |
| ISSN: | 0190-9622 |
| Publisher: | Mosby Elsevier |
| Date Published: | 2020-09-01 |
| Start Page: | 955 |
| End Page: | 957 |
| Language: | English |
| DOI: | 10.1016/j.jaad.2020.01.059 |
| PUBMED: | 32014533 |
| PROVIDER: | scopus |
| PMCID: | PMC8207244 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 1 September 2020 -- Source: Scopus |
